Zacks Investment Research Downgrades Derma Sciences Inc. (DSCI) to Hold
Derma Sciences Inc. (NASDAQ:DSCI) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
According to Zacks, “Derma Sciences, Inc. is engaged in the development, marketing and sales of proprietary and non-proprietary topical, nutrient-based wound care products for the management of certain chronic, non-healing skin ulcerations such as pressure and venous ulcers, surgical incisions and burns. (PRESS RELEASE) “
Separately, TheStreet upgraded Derma Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, August 9th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $7.35.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/zacks-investment-research-downgrades-derma-sciences-inc-dsci-to-hold.html
Derma Sciences (NASDAQ:DSCI) traded down 0.43% during mid-day trading on Tuesday, reaching $4.58. The company had a trading volume of 10,051 shares. The firm’s market capitalization is $129.64 million. The stock’s 50-day moving average is $4.71 and its 200 day moving average is $4.19. Derma Sciences has a 12 month low of $2.85 and a 12 month high of $5.99.
Derma Sciences (NASDAQ:DSCI) last issued its quarterly earnings data on Tuesday, August 9th. The company reported $0.08 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.16. The firm earned $22.20 million during the quarter, compared to the consensus estimate of $22.40 million. Derma Sciences had a negative return on equity of 11.74% and a negative net margin of 21.19%. On average, analysts predict that Derma Sciences will post ($0.04) earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Emerald Acquisition Ltd. acquired a new position in shares of Derma Sciences during the second quarter worth about $202,000. Dimensional Fund Advisors LP raised its position in shares of Derma Sciences by 15.6% in the second quarter. Dimensional Fund Advisors LP now owns 52,535 shares of the company’s stock worth $207,000 after buying an additional 7,086 shares during the period. Jacobs Levy Equity Management Inc. raised its position in shares of Derma Sciences by 170.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 117,271 shares of the company’s stock worth $364,000 after buying an additional 73,911 shares during the period. BlackRock Institutional Trust Company N.A. raised its position in shares of Derma Sciences by 2.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 153,052 shares of the company’s stock worth $603,000 after buying an additional 3,613 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of Derma Sciences by 23.3% in the first quarter. Renaissance Technologies LLC now owns 541,800 shares of the company’s stock worth $1,680,000 after buying an additional 102,500 shares during the period. Institutional investors own 62.44% of the company’s stock.
About Derma Sciences
Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Derma Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.